Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NRAS
REST API REST API
Homo sapiens
NRAS is differentially expressed in 286 experiments: 100 organism parts: mammary gland, tonsil, ... (98 more);, 145 disease states: normal, glioblastoma, ... (143 more);, 93 cell types 363 cell lines 23 compound treatments and 71 other conditions.
Synonyms N-ras
Orthologs RAS2 (Saccharomyces cerevisiae)   nras (Danio rerio)   RASN_CHICK (Gallus gallus)   Nras (Mus musculus)   RAS1 (Saccharomyces cerevisiae)   Nras (Rattus norvegicus)   Ras85D (Drosophila melanogaster)   nras (Xenopus laevis)   A5D7R9_BOVIN (Bos taurus)   O62639_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, GTPase activity, protein binding, visual learning, epidermal growth factor receptor signaling pathway, intracellular, positive regulation of cell proliferation, membrane, Golgi membrane, Golgi apparatus, MAPKKK cascade, insulin receptor signaling pathway, blood coagulation, membrane fraction, GTP catabolic process, GTP binding, activation of MAPKK activity, actin cytoskeleton organization, Ras protein signal transduction, axon guidance, small GTPase mediated signal transduction, nucleotide binding, signal transduction, protein transport, negative regulation of neuron apoptosis, striated muscle cell differentiation, regulation of long-term neuronal synaptic plasticity, leukocyte migration, positive regulation of Rac protein signal transduction, regulation of synaptic transmission, GABAergic, nerve growth factor receptor signaling pathway, Ral guanyl-nucleotide exchange factor activity
InterPro Term MIRO-like, ProtSyn_GTP-bd, Small_GTPase, Small_GTP-bd_dom, Small_GTPase_ARF/SAR, Small_GTPase_Ras, Small_GTPase_Rho, Small_GTPase_Rab_type
UniProt Accession Q5U091, Q9UM97, Q71SP6, P01111, P78460, E5FF39
Gene-Disease Assocation THYROID CARCINOMA, FOLLICULAR; FTC, NOONAN SYNDROME 6; NS6, COLORECTAL CANCER; CRC, JUVENILE MYELOMONOCYTIC LEUKEMIA; JMML
Search EB-eye ENSG00000213281
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (37 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081
SW480
2
E-GEOD-18005, E-GEOD-2509
LNCaP
2
E-GEOD-14464, E-GEOD-14990
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
MCF7
2
E-GEOD-5258, E-MTAB-37
MDA468
2
E-MEXP-440, E-MTAB-62
357 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (49 experiments)

Factor Value U/D Experiments
fibroblast
3
E-GEOD-3204, E-GEOD-26672, E-GEOD-3920
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
mononuclear
2
E-GEOD-26672, E-GEOD-13987
immortalised T lymphocytes
1
E-GEOD-13909
CD8+CD28+
1
E-MEXP-2345
CD8+CD28-
1
E-MEXP-2345
87 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-GEOD-16363, E-MTAB-62, ... (55 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-3726
control
2
E-GEOD-21912, E-GEOD-16363
gastric carcinoma
2
E-GEOD-15460, E-GEOD-2685
acute monoblastic and monocytic leukemia
1
E-MTAB-62
adenocarcinoma
1
E-MTAB-37
iatrogenic Kaposis sarcoma, KSHV-
1
E-MEXP-66
139 more value(s).


Compound treatment

studied in E-TABM-782, E-GEOD-5824, E-TABM-868, E-GEOD-15811, E-GEOD-6462, ... (18 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
dimethyl sulfoxide
2
E-GEOD-5824, E-GEOD-6932
none
3
4
E-GEOD-5824, E-GEOD-412, E-GEOD-2803, E-TABM-868, E-TABM-782, ... (7 experiments)
unknown
1
E-GEOD-7307
MIG control
1
1
E-GEOD-15811
placebo
1
E-MEXP-1327
17 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21374, E-GEOD-2034, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-2509, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MEXP-563 ... (5 experiments)

Genotype
studied in E-GEOD-22056, E-GEOD-3494, E-GEOD-17476, E-GEOD-20115, E-TABM-868, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (30 experiments)

Infection
studied in E-GEOD-9723, E-MEXP-561

Injury
studied in E-GEOD-19743

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636 ... (5 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-18995

Sex
studied in E-GEOD-19743, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, ... (6 experiments)

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.282 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM